Deterding, K., & Pathil-Warth, A. (2017). Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): An open-label, single-arm, phase 2 study. The lancet. Infectious diseases, 17(2), . https://doi.org/10.1016/S1473-3099(16)30408-X
Chicago-Zitierstil (17. Ausg.)Deterding, Katja, und Anita Pathil-Warth. "Ledipasvir Plus Sofosbuvir Fixed-dose Combination for 6 Weeks in Patients with Acute Hepatitis C Virus Genotype 1 Monoinfection (HepNet Acute HCV IV): An Open-label, Single-arm, Phase 2 Study." The Lancet. Infectious Diseases 17, no. 2 (2017). https://doi.org/10.1016/S1473-3099(16)30408-X.
MLA-Zitierstil (9. Ausg.)Deterding, Katja, und Anita Pathil-Warth. "Ledipasvir Plus Sofosbuvir Fixed-dose Combination for 6 Weeks in Patients with Acute Hepatitis C Virus Genotype 1 Monoinfection (HepNet Acute HCV IV): An Open-label, Single-arm, Phase 2 Study." The Lancet. Infectious Diseases, vol. 17, no. 2, 2017, https://doi.org/10.1016/S1473-3099(16)30408-X.